Entering text into the input field will update the search result below

CDC on board with AstraZeneca's Quadrivalent flu vaccine for next year

Feb. 21, 2018 3:26 PM ETAstraZeneca PLC (AZN) StockBy: Douglas W. House, SA News Editor6 Comments
  • The CDC's Advisory Committee on Immunization Practices (ACIP) has voted in favor of renewing its recommendation backing the use of AstraZeneca's (NASDAQ:AZN +0.9%) FLUMIST QUADRIVALENT (influenza vaccine live, intranasal) in the U.S. for the 2018 - 2019 season.
  • ACIP made its recommendation after viewing positive results from a U.S. study in young children aged 2 to less than 4 years assessing the shedding and antibody responses of the H1N1 strain in the live attenuated flu vaccine.

Recommended For You

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC